Svenska
Svenska
News
News
Upcoming events
Subscribe
About us
About us
AlzeCure Pharma in brief
Mission, vision & strategy
A word from the CEO
Organization
Management team
Board of directors
Founders
Scientific advisors
Collaborations and Partnership
History
Career
Open positions
Research & development
Research & development
Project portfolio
NeuroRestore
Alzstatin
Alzheimer’s disease
Depression
Painless
ACD440
TrkA-NAM
Pain
Small molecules
Publications
The patients story
Governance
Governance
Corporate Governance Reports
General meeting
General meetings
Nomination Committee
Board of directors
Management team
Remuneration
Auditors
Articles of association
Investors
Investors
Share Issue 2024
Capital Markets Day 2023
AlzeCure Pharma on First North Premier Growth Market
Certified Adviser
Prospectuses
Share Issue 2024
Rights Issue December 2022
Rights Issue 2022
Listing prospectus 2018
The share
Trading information
Sharecapital development
Dividend policy
Ownership structure
Insiders
Analyst Coverage
Financial reports
Financial calendar
Presentations and Interviews
Press releases
Subscribe
Contact
Media
Media
Press releases
Presentations and Interviews
Video gallery
Image bank
Board of directors
Management
Founders
Logotype
Financial calendar
Subscribe
Contact
Subscribe
Contact
Contact
Office
Investors
Media
Search for:
Search
Media
Press releases
Notice to Annual General Meeting in AlzeCure Pharma AB
April 9, 2025
New data bolstering the anti-inflammatory effect of NeuroRestore ACD856 presented at Alzheimer’s conference
April 7, 2025
AlzeCure Pharma publishes its Annual Report for 2024
April 3, 2025
All press releases
Calendar
Interim report Q1, January-March 2025
May 5, 2025
Annual General Meeting 2025
May 14, 2025
AlzeCure’s CEO, Martin Jönsson attending BIO International in Boston
June 16 - June 19, 2025
All events
